Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp. Company Growth, Stability & Outlook in Seattle
This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Adaptive Biotechnologies Corp. and has not been reviewed or approved by Adaptive Biotechnologies Corp..
What's the stability & growth outlook for Adaptive Biotechnologies Corp.?
Strengths in revenue growth, MRD leadership, and improving profitability are clearly documented at the company level, but none of the materials provide a Seattle-specific signal. Together, these dynamics prevent attributing Stability & Growth drivers to the Seattle office with confidence.
Key Insight for Candidates
Defining pattern: a company-wide pivot to MRD (clonoSEQ) hypergrowth and profitability as Genentech collaboration revenue winds down. For Seattle candidates, day‑to‑day priorities center on MRD adoption, EMR/payer integrations, and tight operating discipline to sustain momentum and reach profitability despite reduced collaboration-driven revenue.Evidence in Action
- MRD Growth Planning — MRD revenue grew 46% to $212.3M in 2025 and comprised 77% of full-year revenue; 2026 MRD guidance is $255–$265M. Seattle teams prioritize clonoSEQ execution, capacity scaling, and cost discipline because growth targets and profitability are anchored in MRD.
- Collaboration Termination Planning — Adaptive and Genentech agreed in August 2025 to terminate their 2018 collaboration effective February 9, 2026. Seattle employees proactively re-align priorities toward MRD and Immune Medicine data partnerships, anticipating reduced historical revenue sources and a shifted mix.
Positive Themes About Adaptive Biotechnologies Corp.
-
Strong Revenue Growth: Company-wide revenue accelerated sharply in 2025 and guidance implies continued expansion into 2026. However, these results do not reference Seattle or a specific office, so no Seattle-anchored driver can be asserted.
-
Strong Market Position & Advantage: The MRD franchise (clonoSEQ) holds distinct regulatory and commercial advantages in hematologic cancers. The materials do not tie these advantages to Seattle operations, preventing a location-specific conclusion.
-
Resilient & Sustainable Growth: Improving adjusted EBITDA and cash flow trends within MRD suggest a strengthening growth trajectory. As the evidence is company-wide without a Seattle signal, it cannot be localized to the Seattle office.
Considerations About Adaptive Biotechnologies Corp.
-
Short-Term or Unsustainable Growth: One‑time and collaboration-related effects (e.g., Genentech amortization and termination) complicate sustainability of headline growth. These risks are described at the enterprise level without Seattle-specific linkage, so they cannot be localized to the Seattle office.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
Adaptive Biotechnologies Corp. FAQs
Is This Your Company?
Claim Profile
